Compare SDST & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDST | TELA |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 51.2M |
| IPO Year | N/A | 2019 |
| Metric | SDST | TELA |
|---|---|---|
| Price | $3.49 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $3.31 |
| AVG Volume (30 Days) | 113.6K | ★ 351.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | N/A | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $1.43 | $0.86 |
| 52 Week High | $70.25 | $3.12 |
| Indicator | SDST | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 44.69 |
| Support Level | $3.06 | $1.09 |
| Resistance Level | $3.74 | $1.28 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 53.57 | 53.57 |
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.